Related Experiment Video

Updated: Apr 30, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K

AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel

Gang Wu1, Xue-Qian Qin2, Jing-Jing Guo2

  • 1Department of General Surgery, Huashan Hospital, Fudan University Shanghai 200040, China ; Department of General Surgery, Renhe Hospital Baoshan District, Shanghai 20043, China.

International Journal of Clinical and Experimental Pathology
|May 13, 2014
PubMed

Insights

Researchers identified key gene and microRNA signatures to predict paclitaxel (PTX) sensitivity in gastric cancer (GC). This discovery offers potential biomarkers for personalized GC treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Paclitaxel (PTX) shows promise in advanced gastric cancer (GC) treatment.
  • Over half of GC patients exhibit poor response to PTX, necessitating sensitivity biomarkers.
  • Identifying predictive markers is crucial for optimizing GC chemotherapy.

Purpose of the Study:

  • To identify gene and microRNA signatures associated with paclitaxel sensitivity in gastric cancer.
  • To propose pathway signatures for predicting PTX response in GC patients.
  • To uncover potential therapeutic targets for improving GC treatment outcomes.

Main Methods:

  • DNA microarray analysis of three gastric cancer cell lines with varying PTX sensitivities.
  • Ingenuity Pathway Analysis to identify enriched signaling pathways.
  • Quantitative PCR and immunoblotting to validate gene and protein expression.
  • MicroRNA expression profiling and construction of a miR-gene network.

Main Results:

  • Identified significantly differentially expressed genes and microRNAs across GC cell lines.
  • ErbB signaling pathway and downstream AKT/ERK signaling pathway implicated in PTX resistance.
  • ErbB3 overexpression and AKT/ERK activation confirmed in PTX-resistant cell lines.
  • A network of 10 differentially expressed microRNAs and their target genes was constructed.

Conclusions:

  • A reliable signature for predicting paclitaxel sensitivity in gastric cancer was uncovered.
  • Overexpression of ErbB3 and activation of AKT/ERK signaling are associated with PTX resistance.
  • Identified microRNAs and genes represent potential therapeutic targets for enhancing PTX efficacy in GC.
Keywords:
AKT signalingDNA microarrayERK signalingErbB signalingGastric cancermicroRNApaclitaxel

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

10.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820